IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry

Abstract

Our study demonstrates IDH mutation and MGMT promoter methylation status independently associate with favorable outcome in TMZ+RT treated glioblastoma patients. However, these biomarkers differentially impact clinical TMZ response.